Novo Nordisk's stock has surged 40% since April, driven by the success of its oral Wegovy pill, which is expected to see significant revenue growth by Q2 2026 as it gains international approvals. This growth is notable especially as competitor Eli Lilly's similar drug, Foundayo, has seen limited success. Despite ongoing sales risks, Novo Nordisk's attractive valuation and optimistic performance outlook keep it a recommended buy for investors.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
